Compare Stocks

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GERN Geron	$3.69 -1.1%	$2.71	$1.64 ▼ $4.05	$2.02B	0.62	11.24 million shs	8.23 million shs
INZY Inozyme Pharma	$4.51 -1.5%	$6.00	$2.69 ▼ $7.80	$278.58M	1.37	616,108 shs	591,071 shs
PLXP PLx Pharma		$0.00	$0.02 ▼ $0.04	$603K	3.79	12.96 million shs	3,000 shs
PRVB Provention Bio	$24.98 +3.1%	$24.58	$3.18 ▼ $25.00	$2.37B	2.47	2.28 million shs	9.12 million shs
TXMD TherapeuticsMD	$1.86 -1.6%	$2.27	$1.86 ▼ $4.73	$21.45M	1.03	21,381 shs	10,248 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GERN Geron	+1.36%	-1.06%	+14.42%	+97.35%	+49.80%
INZY Inozyme Pharma	-1.51%	-12.26%	-19.51%	+6.26%	-23.67%
PLXP PLx Pharma	0.00%	0.00%	0.00%	0.00%	-99.29%
PRVB Provention Bio	0.00%	0.00%	0.00%	0.00%	+2.21%
TXMD TherapeuticsMD	+0.53%	-8.65%	-17.03%	-14.84%	-48.51%

Secret Bull Market Starts in This Unusual Sector (Ad)

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GERN Geron	3.2148 of 5 stars	3.5	3.0	0.0	1.3	1.4	1.7	0.6
INZY Inozyme Pharma	2.0171 of 5 stars	3.5	1.0	0.0	0.0	3.3	3.3	0.0
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GERN Geron	3.00	Buy	$5.33	44.53% Upside
INZY Inozyme Pharma	3.00	Buy	$17.00	276.94% Upside
PLXP PLx Pharma	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	2.00	Hold	N/A	N/A

Current Analyst Ratings

Latest GERN, INZY, PLXP, TXMD, and PRVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
4/10/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
4/9/2024	INZY Inozyme Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
4/9/2024	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
4/8/2024	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
3/15/2024	GERN Geron	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$6.00
3/15/2024	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
3/15/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
3/13/2024	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
3/12/2024	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
2/28/2024	GERN Geron	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GERN Geron	$237K	8,514.62	N/A	N/A	$0.46 per share	8.02
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$2.27 per share	N/A
PLXP PLx Pharma	$4.54M	0.00	N/A	N/A	$1.30 per share	0.00
PRVB Provention Bio	$12.90M	183.54	N/A	N/A	$1.40 per share	17.84
TXMD TherapeuticsMD	$1.30M	16.50	N/A	N/A	$2.77 per share	0.67

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GERN Geron	-$184.13M	-$0.33	N/A	N/A	N/A	-77,691.14%	-63.33%	-44.71%	5/9/2024 (Estimated)
INZY Inozyme Pharma	-$71.17M	-$1.39	N/A	N/A	N/A	N/A	-55.86%	-40.71%	5/14/2024 (Estimated)
PLXP PLx Pharma	-$46.13M	-$1.85	N/A	N/A	N/A	-606.91%	-291.11%	-119.43%	N/A
PRVB Provention Bio	-$113.57M	-$1.53	N/A	N/A	N/A	-880.69%	-103.36%	-69.08%	N/A
TXMD TherapeuticsMD	-$10.28M	N/A	0.00	∞	N/A	N/A	-25.54%	-14.87%	5/20/2024 (Estimated)

Latest GERN, INZY, PLXP, TXMD, and PRVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q4 2023	INZY Inozyme Pharma	-$0.31	-$0.35	-$0.04	-$0.35	N/A	N/A
2/28/2024	Q4 23	GERN Geron	-$0.10	-$0.09	+$0.01	-$0.09	$0.06 million	$0.02 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GERN Geron	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
PLXP PLx Pharma	N/A	N/A	N/A	N/A	N/A
PRVB Provention Bio	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GERN Geron	0.14	3.16	3.16
INZY Inozyme Pharma	0.32	13.36	13.36
PLXP PLx Pharma	N/A	4.79	4.28
PRVB Provention Bio	0.19	1.93	1.92
TXMD TherapeuticsMD	N/A	1.72	1.72

Ownership

Institutional Ownership

Company	Institutional Ownership
GERN Geron	73.71%
INZY Inozyme Pharma	88.30%
PLXP PLx Pharma	21.19%
PRVB Provention Bio	37.39%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
GERN Geron	3.10%
INZY Inozyme Pharma	11.88%
PLXP PLx Pharma	8.95%
PRVB Provention Bio	13.10%
TXMD TherapeuticsMD	1.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GERN Geron	141	546.87 million	529.92 million	Optionable
INZY Inozyme Pharma	59	61.77 million	54.43 million	Optionable
PLXP PLx Pharma	16	29.14 million	26.53 million	Not Optionable
PRVB Provention Bio	82	94.78 million	82.37 million	Not Optionable
TXMD TherapeuticsMD	1	11.53 million	11.39 million	Optionable

GERN, INZY, PLXP, TXMD, and PRVB Headlines

Source	Headline
	TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com americanbankingnews.com - April 19 at 2:14 AM
	TherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosage pharmaceutical-technology.com - April 18 at 9:36 AM
	StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD) americanbankingnews.com - April 13 at 2:18 AM
	TherapeuticsMD Announces Full Year 2023 Financial Results businesswire.com - March 29 at 4:00 PM
	TherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administration pharmaceutical-technology.com - March 28 at 11:17 AM
	25 Countries With Highest Abortion Rates msn.com - March 12 at 3:55 PM
	TherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo Finance sg.finance.yahoo.com - March 10 at 1:13 PM
	TherapeuticsMD Inc TXMD morningstar.com - December 29 at 5:48 PM
	Daily Markets: Today Brings Producer Prices, Retail Sales Data nasdaq.com - November 15 at 9:54 AM
	TherapeuticsMD to Consider Strategic Alternatives marketwatch.com - November 14 at 7:04 PM
	TherapeuticsMD exploring strategic alternatives for company msn.com - November 14 at 6:27 PM
	TherapeuticsMD Announces Third Quarter 2023 Financial Results finance.yahoo.com - November 14 at 6:27 PM
	Boca Raton-based prescription service announces layoffs, says a third of workforce could be cut bizjournals.com - October 4 at 5:11 PM
	TherapeuticsMD Inc. stock falls Wednesday, underperforms market marketwatch.com - September 20 at 6:46 PM
	TherapeuticsMD Inc. stock outperforms market despite losses on the day marketwatch.com - August 15 at 7:00 PM
	TherapeuticsMD Announces Second Quarter 2023 Financial Results finance.yahoo.com - August 14 at 7:50 AM
	Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors finance.yahoo.com - August 9 at 8:38 PM
	TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors marketwatch.com - July 5 at 6:51 PM
	TherapeuticsMD Rejected by FDA, Delay Could Be Fatal thestreet.com - July 4 at 7:28 AM
	TherapeuticsMD Inc. [TXMD] Investment Appeal on the Rise knoxdaily.com - June 19 at 3:12 PM
	TherapeuticsMD: From Fallen And Forgotten To Cash Cow seekingalpha.com - May 23 at 9:28 AM
	TherapeuticsMD Announces First Quarter 2023 Financial Results finance.yahoo.com - May 15 at 4:19 PM
	NeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.com news.google.com - May 14 at 10:42 AM
	NeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybiz news.google.com - May 13 at 7:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Geron

NASDAQ:GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Inozyme Pharma

NASDAQ:INZY

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PLx Pharma

NASDAQ:PLXP

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Provention Bio

NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

TherapeuticsMD

NASDAQ:TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial